about
Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.DC isoketal-modified proteins activate T cells and promote hypertension.Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.Vascular Damage in Resistant Hypertension: TNF-Alpha Inhibition Effects on Endothelial CellsMethoxylated 2'-hydroxychalcones as antiparasitic hit compounds.Circulating matrix metalloproteinases and their inhibitors in hypertension.Adipokines: novel players in resistant hypertension.An update on the pharmacogenetics of treating hypertension.An update on the role of adipokines in arterial stiffness and hypertension.Angiotensinogen Variants among Resistant Hypertensive Patients.Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension.Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.True prevalence of resistant hypertension.Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension.Deregulation of adipokines related to target organ damage on resistant hypertension.Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension.Does Renal Denervation Fit All Resistant Hypertension? The Role of Genetics.Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil.Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity.Gene-Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril.Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension.Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension.Specific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine.Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohortAntihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markersConsistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological targetPolymorphisms in VEGFA gene affect the antihypertensive responses to enalaprilAdiponectin -11377C/G and +276G/T polymorphisms affect adiponectin levels but do not modify responsiveness to therapy in resistant hypertensionModulation of aldosterone levels by -344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertensionEffects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertensionThe white-coat effect is an independent predictor of myocardial ischemia in resistant hypertensionIncreased arterial stiffness in resistant hypertension is associated with inflammatory biomarkersPredictors of silent myocardial ischemia in resistant hypertensive patientsRelationship of left ventricular hypertrophy, age, and renal artery stenosisInvestigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention
P50
Q33812756-5D07BFA9-58D1-4C1A-B058-4C69ADCA119EQ34454645-28566E6F-570F-4B47-A344-D001F48C81F6Q35115111-31677C96-9158-4CD3-8E68-1A7016E22448Q36024251-4754B1B5-BC17-4A79-915E-B7C7B84E7BE7Q36172946-DCF527A7-531D-438A-89B8-0F8F1C2C1A75Q36243812-2293FA03-C45D-4A07-A4E7-835AEFA65F7AQ37975870-5A7B6254-F36C-4828-B508-54599C95B028Q38245895-26275B41-832B-4CC8-92ED-601DACDE2B9AQ38263731-51D4B733-0E05-4466-B368-8DC54DF9E532Q38287245-DD974964-CEB8-42B2-8052-1677FF7AA6BEQ38691627-00B6BB1F-6AA7-4DF5-A671-B41C3167EB8FQ39255610-A4F26A94-33E7-4450-9130-ACFA1637982EQ42717129-02D36803-2BB8-4EBF-B59C-80A30184722BQ44687313-778B9406-9D28-4C37-ACA8-4E3BFC67EF53Q45895088-4EDA5D87-8472-4C39-95F2-C6E9D218907CQ46046358-CE23D608-5FAE-4BAB-899A-C8D5202D4A96Q46915822-D1FB50DE-CE1D-4736-87CF-BD96AC5A830FQ48045081-BA427EFD-6444-495E-8B9E-64EF64530E61Q48161084-4312A8FF-A4C4-4E5B-8EE0-C833047F4680Q50740714-89F545FF-0453-48D3-9F0D-E5E30BF82307Q51102354-91061370-6822-4F6F-B546-18B164D95599Q51437723-2DEFEF7D-22C0-4EE3-A3F5-5C3F44CD4C8BQ53476197-D91B50D9-5310-43F0-9EED-E4AD86BAE43FQ54113467-29498BC8-9F5D-4F8F-BD59-513B2F43BDAFQ54295985-7F7DED95-531A-4056-8A6C-B03630A4DC72Q57302442-79CF8DEA-7857-47F7-AAAF-75E9342B2BD4Q83390480-0A841AA1-1B1A-4053-BCCD-EB7239159EC0Q83606858-2272C9D5-22F9-4984-9AF3-522338711C91Q85195840-48223D19-9CFA-4B5D-AC33-E80CF791858DQ86421639-032BB426-6755-4E0F-84A4-CD610BE1968CQ87032509-3B1A69DA-F21B-4871-80CB-D674CFBEA5B1Q87104750-D170EA2F-08E2-4D99-9018-682D720EE6F6Q87361490-364D8717-583C-4B8D-A0BF-67D1C4F52D68Q87444004-340D8BE0-F287-4E1D-949F-E48BDF4B8AC4Q87447711-5101A269-FCC7-411D-96D4-C521B60B7A94Q87565930-76EA6C8F-8C18-44E2-B60D-F5C2078607A4Q90960051-D9647FF6-B00C-4CCC-A748-E9AB04078604
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vanessa Fontana
@ast
Vanessa Fontana
@en
Vanessa Fontana
@es
Vanessa Fontana
@nl
type
label
Vanessa Fontana
@ast
Vanessa Fontana
@en
Vanessa Fontana
@es
Vanessa Fontana
@nl
prefLabel
Vanessa Fontana
@ast
Vanessa Fontana
@en
Vanessa Fontana
@es
Vanessa Fontana
@nl
P106
P1153
36463249900
P21
P31
P496
0000-0002-0146-9113